The global market for Generic Peptides was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Generic peptides are alternative versions of peptides that have the same or similar amino acid sequences as their brand-name counterparts. These peptides are produced after the expiration of the patent protection for the original peptide, allowing other pharmaceutical companies to manufacture and sell them. Generic peptides are designed to be therapeutically equivalent to the original peptides, providing similar efficacy, safety, and quality.

The market for generic peptides is currently experiencing rapid growth, driven by advancements in the global biopharmaceutical sector. With increasing demand for personalized therapies, generic peptides demonstrate broad application prospects in treating various diseases. The market size is expanding, and sales are continuously growing. As a part of biopharmaceuticals, generic peptides offer higher specificity and lower side effects, making them widely utilized in multiple fields, including cancer treatment, immune modulation, and chronic disease management. In the future, with ongoing technological innovations and in-depth medical research, the generic peptides market is expected to further broaden, providing innovative treatment options for patients worldwide.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Generic Peptides, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Peptides.

The Generic Peptides market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Generic Peptides market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Generic Peptides manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Generic Peptides Market Report

Report Metric	Details
Report Name	Generic Peptides Market
Segment by Type	Hormone Analogs Vasopressin Analogs Calcitonin Generics Other
Segment by Application	Commercial Production Scientific Research Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bachem, PolyPeptide, AmbioPharm, CordenPharma, USV Peptides, ScinoPharm, Piramal Pharma Solutions, CPC Scientific, Dr. Reddy's Laboratories, Omgene Life Sciences, ANYGEN, BCN Peptides, Amphastar Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Generic Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Generic Peptides in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Generic Peptides Market report?

Ans: The main players in the Generic Peptides Market are Bachem, PolyPeptide, AmbioPharm, CordenPharma, USV Peptides, ScinoPharm, Piramal Pharma Solutions, CPC Scientific, Dr. Reddy's Laboratories, Omgene Life Sciences, ANYGEN, BCN Peptides, Amphastar Pharmaceuticals

What are the Application segmentation covered in the Generic Peptides Market report?

Ans: The Applications covered in the Generic Peptides Market report are Commercial Production, Scientific Research, Other

What are the Type segmentation covered in the Generic Peptides Market report?

Ans: The Types covered in the Generic Peptides Market report are Hormone Analogs, Vasopressin Analogs, Calcitonin Generics, Other

1 Generic Peptides Market Overview

1.1 Product Definition

1.2 Generic Peptides by Type

1.2.1 Global Generic Peptides Market Value Comparison by Type (2024 VS 2031)

1.2.2 Hormone Analogs

1.2.3 Vasopressin Analogs

1.2.4 Calcitonin Generics

1.2.5 Other

1.3 Generic Peptides by Application

1.3.1 Global Generic Peptides Market Value by Application (2024 VS 2031)

1.3.2 Commercial Production

1.3.3 Scientific Research

1.3.4 Other

1.4 Global Generic Peptides Market Size Estimates and Forecasts

1.4.1 Global Generic Peptides Revenue 2020-2031

1.4.2 Global Generic Peptides Sales 2020-2031

1.4.3 Global Generic Peptides Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Generic Peptides Market Competition by Manufacturers

2.1 Global Generic Peptides Sales Market Share by Manufacturers (2020-2025)

2.2 Global Generic Peptides Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Generic Peptides Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Generic Peptides, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Generic Peptides, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Generic Peptides, Product Type & Application

2.7 Global Key Manufacturers of Generic Peptides, Date of Enter into This Industry

2.8 Global Generic Peptides Market Competitive Situation and Trends

2.8.1 Global Generic Peptides Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Generic Peptides Players Market Share by Revenue

2.8.3 Global Generic Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Generic Peptides Market Scenario by Region

3.1 Global Generic Peptides Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Generic Peptides Sales by Region: 2020-2031

3.2.1 Global Generic Peptides Sales by Region: 2020-2025

3.2.2 Global Generic Peptides Sales by Region: 2026-2031

3.3 Global Generic Peptides Revenue by Region: 2020-2031

3.3.1 Global Generic Peptides Revenue by Region: 2020-2025

3.3.2 Global Generic Peptides Revenue by Region: 2026-2031

3.4 North America Generic Peptides Market Facts & Figures by Country

3.4.1 North America Generic Peptides Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Generic Peptides Sales by Country (2020-2031)

3.4.3 North America Generic Peptides Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Generic Peptides Market Facts & Figures by Country

3.5.1 Europe Generic Peptides Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Generic Peptides Sales by Country (2020-2031)

3.5.3 Europe Generic Peptides Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Generic Peptides Market Facts & Figures by Region

3.6.1 Asia Pacific Generic Peptides Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Generic Peptides Sales by Region (2020-2031)

3.6.3 Asia Pacific Generic Peptides Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Generic Peptides Market Facts & Figures by Country

3.7.1 Latin America Generic Peptides Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Generic Peptides Sales by Country (2020-2031)

3.7.3 Latin America Generic Peptides Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Generic Peptides Market Facts & Figures by Country

3.8.1 Middle East and Africa Generic Peptides Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Generic Peptides Sales by Country (2020-2031)

3.8.3 Middle East and Africa Generic Peptides Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Generic Peptides Sales by Type (2020-2031)

4.1.1 Global Generic Peptides Sales by Type (2020-2025)

4.1.2 Global Generic Peptides Sales by Type (2026-2031)

4.1.3 Global Generic Peptides Sales Market Share by Type (2020-2031)

4.2 Global Generic Peptides Revenue by Type (2020-2031)

4.2.1 Global Generic Peptides Revenue by Type (2020-2025)

4.2.2 Global Generic Peptides Revenue by Type (2026-2031)

4.2.3 Global Generic Peptides Revenue Market Share by Type (2020-2031)

4.3 Global Generic Peptides Price by Type (2020-2031)

5 Segment by Application

5.1 Global Generic Peptides Sales by Application (2020-2031)

5.1.1 Global Generic Peptides Sales by Application (2020-2025)

5.1.2 Global Generic Peptides Sales by Application (2026-2031)

5.1.3 Global Generic Peptides Sales Market Share by Application (2020-2031)

5.2 Global Generic Peptides Revenue by Application (2020-2031)

5.2.1 Global Generic Peptides Revenue by Application (2020-2025)

5.2.2 Global Generic Peptides Revenue by Application (2026-2031)

5.2.3 Global Generic Peptides Revenue Market Share by Application (2020-2031)

5.3 Global Generic Peptides Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Bachem

6.1.1 Bachem Company Information

6.1.2 Bachem Description and Business Overview

6.1.3 Bachem Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Bachem Generic Peptides Product Portfolio

6.1.5 Bachem Recent Developments/Updates

6.2 PolyPeptide

6.2.1 PolyPeptide Company Information

6.2.2 PolyPeptide Description and Business Overview

6.2.3 PolyPeptide Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.2.4 PolyPeptide Generic Peptides Product Portfolio

6.2.5 PolyPeptide Recent Developments/Updates

6.3 AmbioPharm

6.3.1 AmbioPharm Company Information

6.3.2 AmbioPharm Description and Business Overview

6.3.3 AmbioPharm Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AmbioPharm Generic Peptides Product Portfolio

6.3.5 AmbioPharm Recent Developments/Updates

6.4 CordenPharma

6.4.1 CordenPharma Company Information

6.4.2 CordenPharma Description and Business Overview

6.4.3 CordenPharma Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.4.4 CordenPharma Generic Peptides Product Portfolio

6.4.5 CordenPharma Recent Developments/Updates

6.5 USV Peptides

6.5.1 USV Peptides Company Information

6.5.2 USV Peptides Description and Business Overview

6.5.3 USV Peptides Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.5.4 USV Peptides Generic Peptides Product Portfolio

6.5.5 USV Peptides Recent Developments/Updates

6.6 ScinoPharm

6.6.1 ScinoPharm Company Information

6.6.2 ScinoPharm Description and Business Overview

6.6.3 ScinoPharm Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.6.4 ScinoPharm Generic Peptides Product Portfolio

6.6.5 ScinoPharm Recent Developments/Updates

6.7 Piramal Pharma Solutions

6.7.1 Piramal Pharma Solutions Company Information

6.7.2 Piramal Pharma Solutions Description and Business Overview

6.7.3 Piramal Pharma Solutions Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Piramal Pharma Solutions Generic Peptides Product Portfolio

6.7.5 Piramal Pharma Solutions Recent Developments/Updates

6.8 CPC Scientific

6.8.1 CPC Scientific Company Information

6.8.2 CPC Scientific Description and Business Overview

6.8.3 CPC Scientific Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.8.4 CPC Scientific Generic Peptides Product Portfolio

6.8.5 CPC Scientific Recent Developments/Updates

6.9 Dr. Reddy's Laboratories

6.9.1 Dr. Reddy's Laboratories Company Information

6.9.2 Dr. Reddy's Laboratories Description and Business Overview

6.9.3 Dr. Reddy's Laboratories Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Dr. Reddy's Laboratories Generic Peptides Product Portfolio

6.9.5 Dr. Reddy's Laboratories Recent Developments/Updates

6.10 Omgene Life Sciences

6.10.1 Omgene Life Sciences Company Information

6.10.2 Omgene Life Sciences Description and Business Overview

6.10.3 Omgene Life Sciences Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Omgene Life Sciences Generic Peptides Product Portfolio

6.10.5 Omgene Life Sciences Recent Developments/Updates

6.11 ANYGEN

6.11.1 ANYGEN Company Information

6.11.2 ANYGEN Description and Business Overview

6.11.3 ANYGEN Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.11.4 ANYGEN Generic Peptides Product Portfolio

6.11.5 ANYGEN Recent Developments/Updates

6.12 BCN Peptides

6.12.1 BCN Peptides Company Information

6.12.2 BCN Peptides Description and Business Overview

6.12.3 BCN Peptides Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.12.4 BCN Peptides Generic Peptides Product Portfolio

6.12.5 BCN Peptides Recent Developments/Updates

6.13 Amphastar Pharmaceuticals

6.13.1 Amphastar Pharmaceuticals Company Information

6.13.2 Amphastar Pharmaceuticals Description and Business Overview

6.13.3 Amphastar Pharmaceuticals Generic Peptides Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Amphastar Pharmaceuticals Generic Peptides Product Portfolio

6.13.5 Amphastar Pharmaceuticals Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Generic Peptides Industry Chain Analysis

7.2 Generic Peptides Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Generic Peptides Production Mode & Process Analysis

7.4 Generic Peptides Sales and Marketing

7.4.1 Generic Peptides Sales Channels

7.4.2 Generic Peptides Distributors

7.5 Generic Peptides Customer Analysis

8 Generic Peptides Market Dynamics

8.1 Generic Peptides Industry Trends

8.2 Generic Peptides Market Drivers

8.3 Generic Peptides Market Challenges

8.4 Generic Peptides Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Piramal Pharma Solutions

CPC Scientific

Dr. Reddy’s Laboratories

Omgene Life Sciences

AnyGen Co.

BCN Peptides

Amphastar Pharmaceuticals

List of Tables

Table 1. Global Generic Peptides Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Generic Peptides Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Generic Peptides Market Competitive Situation by Manufacturers in 2024

Table 4. Global Generic Peptides Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Generic Peptides Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Generic Peptides Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Generic Peptides Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Generic Peptides Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Generic Peptides, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Generic Peptides, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Generic Peptides, Product Type & Application

Table 12. Global Key Manufacturers of Generic Peptides, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Generic Peptides by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Peptides as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Generic Peptides Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Generic Peptides Sales by Region (2020-2025) & (K Units)

Table 18. Global Generic Peptides Sales Market Share by Region (2020-2025)

Table 19. Global Generic Peptides Sales by Region (2026-2031) & (K Units)

Table 20. Global Generic Peptides Sales Market Share by Region (2026-2031)

Table 21. Global Generic Peptides Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Generic Peptides Revenue Market Share by Region (2020-2025)

Table 23. Global Generic Peptides Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Generic Peptides Revenue Market Share by Region (2026-2031)

Table 25. North America Generic Peptides Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Generic Peptides Sales by Country (2020-2025) & (K Units)

Table 27. North America Generic Peptides Sales by Country (2026-2031) & (K Units)

Table 28. North America Generic Peptides Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Generic Peptides Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Generic Peptides Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Generic Peptides Sales by Country (2020-2025) & (K Units)

Table 32. Europe Generic Peptides Sales by Country (2026-2031) & (K Units)

Table 33. Europe Generic Peptides Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Generic Peptides Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Generic Peptides Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Generic Peptides Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Generic Peptides Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Generic Peptides Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Generic Peptides Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Generic Peptides Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Generic Peptides Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Generic Peptides Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Generic Peptides Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Generic Peptides Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Generic Peptides Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Generic Peptides Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Generic Peptides Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Generic Peptides Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Generic Peptides Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Generic Peptides Sales (K Units) by Type (2020-2025)

Table 51. Global Generic Peptides Sales (K Units) by Type (2026-2031)

Table 52. Global Generic Peptides Sales Market Share by Type (2020-2025)

Table 53. Global Generic Peptides Sales Market Share by Type (2026-2031)

Table 54. Global Generic Peptides Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Generic Peptides Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Generic Peptides Revenue Market Share by Type (2020-2025)

Table 57. Global Generic Peptides Revenue Market Share by Type (2026-2031)

Table 58. Global Generic Peptides Price (US$/Unit) by Type (2020-2025)

Table 59. Global Generic Peptides Price (US$/Unit) by Type (2026-2031)

Table 60. Global Generic Peptides Sales (K Units) by Application (2020-2025)

Table 61. Global Generic Peptides Sales (K Units) by Application (2026-2031)

Table 62. Global Generic Peptides Sales Market Share by Application (2020-2025)

Table 63. Global Generic Peptides Sales Market Share by Application (2026-2031)

Table 64. Global Generic Peptides Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Generic Peptides Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Generic Peptides Revenue Market Share by Application (2020-2025)

Table 67. Global Generic Peptides Revenue Market Share by Application (2026-2031)

Table 68. Global Generic Peptides Price (US$/Unit) by Application (2020-2025)

Table 69. Global Generic Peptides Price (US$/Unit) by Application (2026-2031)

Table 70. Bachem Company Information

Table 71. Bachem Description and Business Overview

Table 72. Bachem Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Bachem Generic Peptides Product

Table 74. Bachem Recent Developments/Updates

Table 75. PolyPeptide Company Information

Table 76. PolyPeptide Description and Business Overview

Table 77. PolyPeptide Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. PolyPeptide Generic Peptides Product

Table 79. PolyPeptide Recent Developments/Updates

Table 80. AmbioPharm Company Information

Table 81. AmbioPharm Description and Business Overview

Table 82. AmbioPharm Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. AmbioPharm Generic Peptides Product

Table 84. AmbioPharm Recent Developments/Updates

Table 85. CordenPharma Company Information

Table 86. CordenPharma Description and Business Overview

Table 87. CordenPharma Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. CordenPharma Generic Peptides Product

Table 89. CordenPharma Recent Developments/Updates

Table 90. USV Peptides Company Information

Table 91. USV Peptides Description and Business Overview

Table 92. USV Peptides Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. USV Peptides Generic Peptides Product

Table 94. USV Peptides Recent Developments/Updates

Table 95. ScinoPharm Company Information

Table 96. ScinoPharm Description and Business Overview

Table 97. ScinoPharm Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. ScinoPharm Generic Peptides Product

Table 99. ScinoPharm Recent Developments/Updates

Table 100. Piramal Pharma Solutions Company Information

Table 101. Piramal Pharma Solutions Description and Business Overview

Table 102. Piramal Pharma Solutions Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Piramal Pharma Solutions Generic Peptides Product

Table 104. Piramal Pharma Solutions Recent Developments/Updates

Table 105. CPC Scientific Company Information

Table 106. CPC Scientific Description and Business Overview

Table 107. CPC Scientific Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. CPC Scientific Generic Peptides Product

Table 109. CPC Scientific Recent Developments/Updates

Table 110. Dr. Reddy's Laboratories Company Information

Table 111. Dr. Reddy's Laboratories Description and Business Overview

Table 112. Dr. Reddy's Laboratories Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Dr. Reddy's Laboratories Generic Peptides Product

Table 114. Dr. Reddy's Laboratories Recent Developments/Updates

Table 115. Omgene Life Sciences Company Information

Table 116. Omgene Life Sciences Description and Business Overview

Table 117. Omgene Life Sciences Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Omgene Life Sciences Generic Peptides Product

Table 119. Omgene Life Sciences Recent Developments/Updates

Table 120. ANYGEN Company Information

Table 121. ANYGEN Description and Business Overview

Table 122. ANYGEN Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. ANYGEN Generic Peptides Product

Table 124. ANYGEN Recent Developments/Updates

Table 125. BCN Peptides Company Information

Table 126. BCN Peptides Description and Business Overview

Table 127. BCN Peptides Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. BCN Peptides Generic Peptides Product

Table 129. BCN Peptides Recent Developments/Updates

Table 130. Amphastar Pharmaceuticals Company Information

Table 131. Amphastar Pharmaceuticals Description and Business Overview

Table 132. Amphastar Pharmaceuticals Generic Peptides Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Amphastar Pharmaceuticals Generic Peptides Product

Table 134. Amphastar Pharmaceuticals Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Generic Peptides Distributors List

Table 138. Generic Peptides Customers List

Table 139. Generic Peptides Market Trends

Table 140. Generic Peptides Market Drivers

Table 141. Generic Peptides Market Challenges

Table 142. Generic Peptides Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

Table 146. Authors List of This Report

List of Figures

Figure 1. Product Picture of Generic Peptides

Figure 2. Global Generic Peptides Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Generic Peptides Market Share by Type: 2024 & 2031

Figure 4. Hormone Analogs Product Picture

Figure 5. Vasopressin Analogs Product Picture

Figure 6. Calcitonin Generics Product Picture

Figure 7. Other Product Picture

Figure 8. Global Generic Peptides Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Generic Peptides Market Share by Application: 2024 & 2031

Figure 10. Commercial Production

Figure 11. Scientific Research

Figure 12. Other

Figure 13. Global Generic Peptides Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Generic Peptides Market Size (2020-2031) & (US$ Million)

Figure 15. Global Generic Peptides Sales (2020-2031) & (K Units)

Figure 16. Global Generic Peptides Average Price (US$/Unit) & (2020-2031)

Figure 17. Generic Peptides Report Years Considered

Figure 18. Generic Peptides Sales Share by Manufacturers in 2024

Figure 19. Global Generic Peptides Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Generic Peptides Players: Market Share by Revenue in Generic Peptides in 2024

Figure 21. Generic Peptides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Generic Peptides Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Generic Peptides Sales Market Share by Country (2020-2031)

Figure 24. North America Generic Peptides Revenue Market Share by Country (2020-2031)

Figure 25. United States Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Generic Peptides Sales Market Share by Country (2020-2031)

Figure 28. Europe Generic Peptides Revenue Market Share by Country (2020-2031)

Figure 29. Germany Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Generic Peptides Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Generic Peptides Revenue Market Share by Region (2020-2031)

Figure 36. China Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Generic Peptides Sales Market Share by Country (2020-2031)

Figure 44. Latin America Generic Peptides Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Generic Peptides Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Generic Peptides Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Generic Peptides Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Generic Peptides by Type (2020-2031)

Figure 54. Global Revenue Market Share of Generic Peptides by Type (2020-2031)

Figure 55. Global Generic Peptides Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Generic Peptides by Application (2020-2031)

Figure 57. Global Revenue Market Share of Generic Peptides by Application (2020-2031)

Figure 58. Global Generic Peptides Price (US$/Unit) by Application (2020-2031)

Figure 59. Generic Peptides Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions